Tuesday, May 16, 2017

Welcome and Opening Keynote
5:00 p.m. – 6:00 p.m.

SWI/SNF (BAF) complex mutations in cancer: Mechanisms and vulnerabilities
Charles W. M. Roberts, St. Jude Children’s Research Hospital, Memphis, Tennessee

Welcome Reception
6:00 p.m. – 8:30 p.m.

Wednesday, May 17, 2017

Plenary Session 1: Genomics
Session Chair: David Malkin, The Hospital for Sick Children, Toronto, Ontario, Canada
8:00 a.m. – 10:00 a.m.

Modeling Sarcoma Susceptibility: The Li-Fraumeni Syndrome Paradigm
David Malkin

Translating genomic risk into an early detection strategy for sarcoma
David M. Thomas, Garvan Institute of Medical Research, Darlinghurst, New South Wales, Australia

Targeting the expression of EWS-FLI1
Natasha J. Caplen, National Cancer Institute, Bethesda, Maryland
Plenary Session 2: 'Omics
Session Chair: Todd R. Golub, Broad Institute of MIT and Harvard, Cambridge, Massachusetts
10:30 a.m. – 12:30 p.m.

Targeting ATP-dependent chromatin remodeling complexes in human sarcomas
Cigall Kadoch, Dana-Farber Cancer Institute, Boston, Massachusetts

Title to be announced
Todd R. Golub

Chromatin regulators as cancer dependencies
Christopher R. Vakoc, Cold Spring Harbor Laboratory Cancer Center, Cold Spring Harbor, New York

Plenary Session 3: New Model Systems
Session Chair: David M. Langenau, Massachusetts General Hospital, Charlestown, Massachusetts
2:30 p.m. – 4:30 p.m.

Title to be announced
Elaine A. Ostrander, NIH-NHGRI, Bethesda, Maryland

A dog in the fight: How pet dogs with cancer can inform clinical research
Will Eward, Duke University, Durham, North Carolina

Conserved muscle stem cell programs drive rhabdomyosarcoma growth
David M. Langenau

Poster Session A / Reception
4:30 p.m. – 7:00 p.m.

Thursday, May 18, 2017

Plenary Session 4: Signaling Perturbations and Targeted Therapeutics
Session Chair: Benjamin A. Alman, Duke University, Durham, North Carolina
8:00 a.m. – 10:00 a.m.
CDK4 inhibition and senescence: pathway understanding leads to rational drug combinations
Andrew Koff, Memorial Sloan Kettering Cancer Center, New York, New York

Hypoxia, metabolism, and sarcoma progression
M. Celeste Simon, Abramson Family Cancer Research Institute, Philadelphia, Pennsylvania

Cellular heterogeneity in sarcomas: All cells are not created equal
Benjamin A. Alman

Plenary Session 5: Neurofibromatosis and MPNST
Session Chair: Ping Chi, Memorial Sloan Kettering Cancer Center, New York, New York
10:30 a.m. – 12:45 p.m.

Molecular pathogenesis of malignant peripheral nerve sheath tumor
Ping Chi

Using gene expression analyses to identify MPNST therapeutics
Nancy Ratner, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio

Natural history of peripheral nerve sheath tumors in NF1: Identification and characterization of malignant precursor lesions
Brigitte C. Widemann, National Cancer Institute, Bethesda, Maryland

Molecular pathogenesis and drug synergy in a zebrafish model of NF1-associated MPNST
A. Thomas Look, Dana-Farber Cancer Institute, Boston, Massachusetts

Poster Session B / Lunch
12:45 p.m. – 3:15 p.m.

Plenary Session 6: Novel Biologic Mechanisms
Session Chair: Cristina K. Antonescu, Memorial Sloan Kettering Cancer Center, New York, New York
3:15 p.m. – 5:15 p.m.

Integrin-alpha 10 signaling pathway drives sarcomagenesis in mxyofibrosarcoma and undifferentiated pleomorphic sarcoma
Samuel Singer, Memorial Sloan Kettering Cancer Center, New York, New York
Emerging genetic mechanisms in undifferentiated round cell sarcomas
Cristina Antonescu

Autophagy in alveolar soft part sarcomagenesis
Kevin B. Jones, University of Utah Huntsman Cancer Institute, Salt Lake City, Utah

Friday, May 19, 2017

Plenary Session 7: Immune Modulation and Microenvironment
Session Chair: Irene L. Andrulis, University of Toronto Mount Sinai Hospital, Toronto, Ontario, Canada
8:00 a.m. – 10:00 a.m.

Immune mechanisms in gastrointestinal stromal tumor
Ronald P. DeMatteo, Memorial Sloan Kettering Cancer Center, New York, New York
Title to be announced
David G. Kirsch, Duke University Medical Center, Durham, North Carolina

Variation in the immune cell infiltrate and expression of PD-L1 in sarcoma subtypes
Irene L. Andrulis

Plenary Session 8: Disease Progression
Session Chair: Jonathan A. Fletcher, Brigham and Women's Hospital, Boston, Massachusetts
10:30 a.m.-12:30 p.m.

Title to be announced
D. Wade Clapp, Indiana University School of Medicine, Indianapolis, Indiana

Title to be announced
Jonathan A. Fletcher

Cell plasticity and metastatic progression of Ewing sarcoma
Elizabeth R. Lawlor, University of Michigan, Ann Arbor, Michigan